Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] EXAMINE: targeting risk and treatment in diabetes

Two common medical fallacies are that more is better and every drug in a class is the same (known as a class effect). The association of dipeptidyl peptidase-4 (DDP-4) inhibitors with an increased risk of heart failure is supported by the SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) trials.1,2 With the publication of the much anticipated TECOS trial,3 this adverse effect appears to not be a class effect because sitagliptin did not cause an increase in the risk of heart failure. All five available DPP-4 inhibitors have similarity of either a primary or secondary amine group, which contributes to electrostatic interactions with DPP-4.

email